NCT00159471View on ClinicalTrials.gov

Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.

NATerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

July 31, 2006

Conditions
Pancreatic Cancer
Interventions
DRUG

capecitabine, gemcitabine, docetaxel

Trial Locations (1)

90033

U.S.C / Norris Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

University of Southern California

OTHER